Bose Officially Introduces SoundControl Hearing Aids
First FDA-Cleared Direct-to-Consumer Hearing Aid
Revolutionary Bose App Clinically Proven for Audiologist-Quality Results
News provided by
Share this article
Share this article
FRAMINGHAM, Mass., May 11, 2021 /PRNewswire/ Today, Bose announces the new SoundControl™ Hearing Aids the first FDA-cleared, direct-to-consumer hearing aid developed for adults with perceived mild to moderate hearing loss. Paired with the revolutionary Bose Hear app, users can fit, program, and control a SoundControl Hearing Aid for clinically proven, audiologist-quality results without a doctor visit, hearing test, or prescription. And they can make setting adjustments themselves, in real-time and real-world environments, without assistance from a healthcare professional. SoundControl Hearing Aids come with a 90-day risk-free trial, dedicated product support, and are available at a fraction of the cost of most conventional hearing aids. They
Image: Bose
While you might expect that Bose’s latest gadget has something to do with music, it’s actually a lot closer to wearable health tech. In fact, they’re actually FDA-cleared, self-fitted hearing aids designed for people with mild to moderate hearing loss.
Advertisement
The Bose SoundControl Hearing Aids are technologically intriguing. They feature a behind-the-ear, receiver-in-canal design with the help of a companion app, allowing users to customize their settings using two controls. The “World Volume” control amplifies quiet sounds to louder ones, while the Treble/Bass setting can be used to fine-tune vocal frequencies. It also supports preset modes so you can, for instance, focus on conversations in loud environments, or choose a setting that lets in all ambient sounds for better awareness.
Bose gets into hearing aid business with new FDA-cleared SoundControl hearing aids
Available in five states starting on May 18th May 11, 2021, 1:25pm EDT
If you buy something from a Verge link, Vox Media may earn a commission. See our ethics statement.
Share this story
Image: Bose
Bose announced today that it will begin selling direct-to-consumer SoundControl hearing aids for adults with mild to moderate hearing loss on May 18th. They’ll cost $849.95 and will be sold directly by Bose in five states Massachusetts, Montana, North Carolina, South Carolina, and Texas before they’re available nationally.
The hearing aids are meant to be fit and controlled by the wearer without needing to see an audiologist for a hearing test and professional fitting. They use standard hearing aid batteries that Bose says will last up to four days if used 14 hours a day. Volume, treble and bass, and modes for different listening environments can be adjusted and preset in the Bose
Breaking the cycle
Promoting better menstrual literacy will help clinicians assess and manage the symptoms associated with dysmenorrhea, according to a new Irish study.
Peter Doyle reports
More needs to be done to remove the stigma surrounding menstruation and menstrual pain, an award-winning Irish research paper is reporting.
Defined as cramping pain in the lower abdomen occurring just before or during menstruation, menstrual pain, also known as primary dysmenorrhea (PD), affects the majority of women of reproductive age.
Researchers from Centre for Pain Research, National University of Ireland Galway (NUIG), and the NUIG’s School of Psychology recently investigated the impact the condition was having on third-level students.
2 Min Read
NEW YORK (Reuters) -A U.S. regulator barred a former Goldman Sachs & Co research analyst from the brokerage industry for insider trading in two companies that the company was about to upgrade, and for lying about his trading.
FILE PHOTO: Signage is seen outside of the Financial Industry Regulatory Authority (FINRA) offices in Manhattan, New York City, U.S., September 11, 2020. REUTERS/Andrew Kelly/File Photo
The Financial Industry Regulatory Authority (FINRA) said Brian Maguire bought $850,000 worth of shares in two companies last April and June after receiving internal emails that a fellow analyst would soon raise the companies’ ratings to “buy” from “neutral.”